OF OBJECTIVES: Boston University Medical Center (BUMC), a consortium of Boston University and Boston Medical Center, proposes a National Center for Emerging Infectious Diseases and Biodefense (NCEIDB). The primary objectives are: 1) To construct a safe, secure facility for cutting-edge basic, translational, animal and clinical research on emerging infectious diseases including category A, B and C agents integrated into the research and emergency-preparedness environments of BUMC, Boston, and the nation 2) To put into place comprehensive research, development and training programs to achieve the objectives of the NIAID's Strategic Plan for Biodefense Research. The NCEIDB incorporates 18 intramural core resources and expertise for basic molecular studies aimed at identifying target molecules, identifying small molecules and biologicals that interact with these molecules for diagnostic, preventative or therapeutic purposes, a plan for producing such products, facilites for assessment of the interaction of pathogens with these molecules in vitro, and a comprehensive approach for evaluations in vivo in animals and humans. The proposed NCEIDB is responsive to all of the required elements and is distinguished by unique features including: integration of the facility into a biomedical """"""""research park"""""""", an aggressive time-line for project completion, integration with a premier urban academic medical center, coordination with the New England Regional Primate Research Center to build dedicated non-human primate breeding and quarantine facilities, coordination with the Massachusetts Biological Laboratories for production of vaccines and biologicals under GMP conditions, coordination with unique resource to produce chemical libraries and extensive planning for the training mission of the NCEIDB.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Construction Cooperative Agreement (UC6)
Project #
3UC6AI058618-01S1
Application #
7263766
Study Section
Special Emphasis Panel (ZAI1)
Program Officer
Khoshbin, Fred
Project Start
2003-09-30
Project End
2012-06-30
Budget Start
2003-09-30
Budget End
2012-06-30
Support Year
1
Fiscal Year
2006
Total Cost
$12,999,750
Indirect Cost
Name
Boston University
Department
Type
Schools of Medicine
DUNS #
604483045
City
Boston
State
MA
Country
United States
Zip Code
02118
Manhart, Whitney A; Pacheco, Jennifer R; Hume, Adam J et al. (2018) A Chimeric Lloviu Virus Minigenome System Reveals that the Bat-Derived Filovirus Replicates More Similarly to Ebolaviruses than Marburgviruses. Cell Rep 24:2573-2580.e4
Olejnik, Judith; Nelson, Emily V (2017) Analyzing Apoptosis Induction and Evasion in Ebola Virus-Infected Cells. Methods Mol Biol 1628:227-241
Rossignol, Evan D; Peters, Kristen N; Connor, John H et al. (2017) Zika virus induced cellular remodelling. Cell Microbiol 19:
Brauburger, Kristina; Cressey, Tessa; Mühlberger, Elke (2017) Nonradioactive Northern Blot Analysis to Detect Ebola Virus Minigenomic mRNA. Methods Mol Biol 1628:143-159
Ruedas, John B; Connor, John H (2017) Generating Recombinant Vesicular Stomatitis Viruses for Use as Vaccine Platforms. Methods Mol Biol 1581:203-222
Cressey, Tessa; Brauburger, Kristina; Mühlberger, Elke (2017) Modeling Ebola Virus Genome Replication and Transcription with Minigenome Systems. Methods Mol Biol 1628:79-92
Speranza, Emily; Connor, John H (2017) Host Transcriptional Response to Ebola Virus Infection. Vaccines (Basel) 5:
Nelson, Emily V; Pacheco, Jennifer R; Hume, Adam J et al. (2017) An RNA polymerase II-driven Ebola virus minigenome system as an advanced tool for antiviral drug screening. Antiviral Res 146:21-27
Mounce, Bryan C; Olsen, Michelle E; Vignuzzi, Marco et al. (2017) Polyamines and Their Role in Virus Infection. Microbiol Mol Biol Rev 81:
Hume, Adam J; Ames, Joshua; Rennick, Linda J et al. (2016) Inactivation of RNA Viruses by Gamma Irradiation: A Study on Mitigating Factors. Viruses 8:

Showing the most recent 10 out of 15 publications